Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer

Molecular Cancer Therapeutics

Volumn 13, Issue 4, 2014, Pages 890-901

  Gross, Matt I ^a   Demo, Susan D ^a   Dennison, Jennifer B ^b   Chen, Lijing ^a   Chernov Rogan, Tania ^a   Goyal, Bindu ^a   Janes, Julie R ^a   Laidig, Guy J ^a   Lewis, Evan R ^a   Li, Jim ^a   MacKinnon, Andrew L ^a   Parlati, Francesco ^a   Rodriguez, Mirna L M ^a   Shwonek, Peter J ^a   Sjogren, Eric B ^a   Stanton, Timothy F ^a   Wang, Taotao ^a   Yang, Jinfu ^a   Zhao, Frances ^a   Bennett, Mark K ^a  

^a Calithera Biosciences ^*  (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CB 839; DRUG METABOLITE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GLUTAMIC ACID; GLUTAMINASE; GLUTAMINE; GLUTATHIONE; HYDROLASE INHIBITOR; PACLITAXEL; UNCLASSIFIED DRUG; BENZENEACETAMIDE DERIVATIVE; BIS-2-(5-PHENYLACETAMIDO-1,2,4-THIADIAZOL-2-YL)ETHYL SULFIDE; CB-839; ENZYME INHIBITOR; SULFIDE; THIADIAZOLE DERIVATIVE;

ADULT; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CASE REPORT; CELL LINE; CITRIC ACID CYCLE; DRUG POTENCY; DRUG SENSITIVITY; ENZYME INHIBITION; FEMALE; HCC 1806 CELL; HUMAN; JIMT 1 CELL; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEADY STATE; TRIPLE NEGATIVE BREAST CANCER; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; DOSE RESPONSE; DRUG SCREENING; EXPERIMENTAL MAMMARY NEOPLASM; MIDDLE AGED; NEOPLASMS, BASAL CELL; ORAL DRUG ADMINISTRATION; PATHOLOGY; SCID MOUSE; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELL LINE;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; BENZENEACETAMIDES; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEMALE; GLUTAMINASE; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, SCID; MIDDLE AGED; NEOPLASMS, BASAL CELL; SULFIDES; THIADIAZOLES; TRIPLE NEGATIVE BREAST NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84904645105     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0870     Document Type: Article

References (33)

1. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009;324:1029-33.
2. Koppenol WH, Bounds PL, Dang CV. Otto Warburg's contributions to current concepts of cancer metabolism. Nat Rev Cancer 2011;11:325-37.
3. Wise DR, Thompson CB. Glutamine addiction: a new therapeutic target in cancer. Trends Biochem Sci 2010;35:427-33.
4. Hensley CT, Wasti AT, Deberardinis RJ. Glutamine and cancer: cell biology, physiology, and clinical opportunities. J Clin Invest 2013;123:3678-84.
5. Gao P, Tchernyshyov I, Chang TC, Lee YS, Kita K, Ochi T, et al. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 2009;458:762-5.
6. Wang JB, Erickson JW, Fuji R, Ramachandran S, Gao P, Dinavahi R, et al. Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell 2010;18:207-19.
7. Seltzer MJ, Bennett BD, Joshi AD, Gao P, Thomas AG, Ferraris DV, et al. Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res 2010;70:8981-7.
8. Cheng T, Sudderth J, Yang C, Mullen AR, Jin ES, Mates JM, et al. Pyruvate carboxylase is required for glutamine-independent growth of tumor cells. Proc Natl Acad Sci U S A 2011;108:8674-9.
9. Le A, Lane A, Hamaker M, Bose S, Gouw A, Barbi J, et al. Glucoseindependent glutamine metabolism via TCA cycling for proliferation and survival in B cells. Cell Metabolism 2012;15:110-21.
10. van den Heuvel AP, Jing J, Wooster RF, Bachman KE. Analysis of glutamine dependency in non-small cell lung cancer: GLS1 splice variant GAC is essential for cancer cell growth. Cancer Biol Ther 2012;13:1185-94.
11. Yuneva MO, Fan TW, Allen TD, Higashi RM, Ferraris DV, Tsukamoto T, et al. The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type. Cell Metab 2012;15:157-70.
12. Son J, Lyssiotis CA, Ying H, Wang X, Hua S, Ligorio M, et al. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature 2013;496:101-5.
13. Gameiro PA, Yang J, Metelo AM, Perez-Carro R, Baker R, Wang Z, et al. In vivo HIF-mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation. Cell Metab 2013;17:372-85.
14. Timmerman LA, Holton T, Yuneva M, Louie RJ, Padro M, Daemen A, et al. Glutamine sensitivity analysis identifies the xCT Antiporter as a common triple-negative breast tumor therapeutic target. Cancer Cell 2013;24:450-65.
15. Cassago A, Ferreira AP, Ferreira IM, Fornezari C, Gomes ER, Greene KS, et al. Mitochondrial localization and structure-based phosphate activation mechanism of glutaminase C with implications for cancer metabolism. Proc Natl Acad Sci U S A 2012;109:1092-7.
16. Kung HN, Marks JR, Chi JT. Glutamine synthetase is a genetic determinant of cell type-specific glutamine independence in breast epithelia. PLoS Genet 2011;7:e1002229.
17. Catane R, Von Hoff DD, Glaubiger DL, Muggia FM. Azaserine, DON, and azotomycin: three diazo analogs of L-glutamine with clinical antitumor activity. Cancer Treat Rep 1979;63:1033-8.
18. Robinson MM, McBryant SJ, Tsukamoto T, Rojas C, Ferraris DV, Hamilton SK, et al. Novel mechanism of inhibition of rat kidney-type glutaminase by bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES). Biochem J 2007;406:407-14.
19. Shukla K, Ferraris DV, Thomas AG, Stathis M, Duvall B, Delahanty G, et al. Design, synthesis, and pharmacological evaluation of bis-2-(5- phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide 3 (BPTES) analogs as glutaminase inhibitors. J Med Chem 2012;55:10551-63.
20. Kisner DL, Catane R, Muggia FM. The rediscovery of DON (6-diazo-5- oxo-L-norleucine). Recent Results Cancer Res 1980;74:258-63.
21. Hartwick EW, Curthoys NP. BPTES inhibition of hGA(124-551), a truncated form of human kidney-type glutaminase. J Enzyme Inhib Med Chem 2012;27:861-7.
22. DeLaBarre B, Gross S, Fang C, Gao Y, Jha A, Jiang F, et al. Full-length human glutaminase in complex with an allosteric inhibitor. Biochemistry 2011;50:10764-70.
23. Thangavelu K, Pan C, Karlberg T, Balaji G, Uttamchandani M, Suresh V, et al. Structural basis for the allosteric inhibitory mechanism of human kidney-type glutaminase (KGA) and its regulation by Raf-Mek-Erk signaling in cancer cell metabolism. PNAS 2012;109:7705-10.
24. Qie S, Chu C, Li W, Wang C, Sang N. ErbB2 activation upregulates glutaminase 1 expression which promotes breast cancer cell proliferation. J Cell Biochem 2014;115:498-509.
25. Newcomb RW, inventor; Elan Pharmaceuticals I, assignee. Selective inhibition of glutaminase by bis-thiadiazoles. United States patent US 6451828. 2002 Sep 17.
26. Li J, Chen L, Goyal B, Laidig G, Stanton TF, Sjogren EB, inventors; Calithera Biosciences I, assignee. Heterocyclic inhibitors of glutaminase. United States patent US 8604016. 2013 Dec 10.
27. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006;10:515-27.
28. Krebs HA. Metabolism of amino-acids: the synthesis of glutamine from glutamic acid and ammonia, and the enzymic hydrolysis of glutamine in animal tissues. Biochem J 1935;29:1951-69.
29. Curthoys NP, Watford M. Regulation of glutaminase activity and glutamine metabolism. Annu Rev Nutr 1995;15:133-59.
30. Bannai S, Tateishi N. Role of membrane transport in metabolism and function of glutathione in mammals. J Membr Biol 1986;89:1-8.
31. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012;490:61-70.
32. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012;483:603-7.
33. Tanner M, Kapanen AI, Junttila T, Raheem O, Grenman S, Elo J, et al. Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer. Mol Cancer Ther 2004;3:1585-92.